China’s National Healthcare Security Administration (NHSA) announced on Jan. 10 that it will not include Pfizer’s Paxlovid in its national reimbursement plan due to its high cost.
The negotiation between China and Pfizer on Tuesday failed because Pfizer considered China “a middle-income country,” and the price proposed by Beijing was lower than what Pfizer would have accepted, according to several media outlets.
Under the current Chinese medical insurance policy, the reimbursement for Paxlovid will continue until the end of March, the NHSA said.
NHSA gave conditional approval of Paxlovid for treating COVID-19 in February last year, making it the first oral COVID treatment pill cleared in the country….